Cardiac-specific gene expression is intricately regulated in response to developmental, hormonal, and hemodynamic stimuli. To test whether cardiac muscle might be a target for regulation by peptide growth factors, the effect of three growth factors on the actin and myosin gene families was investigated by Northern blot analysis in cultured neonatal rat cardiac myocytes.
the most intensively studied of this ensemble. In principle, the transition from compensatory hypertrophy to intractable failure may in part be due to anomalous transcription of genes that encode proteins essential for cardiac function. However, while #MHC are thought to diminish myocardial contractility, on the basis of slower cross-brige cycling (6) , the possible physiologic implications of altered actin expression have not been proven. Thus, the changes produced by hemodynamic stress may recapitulate a fetal program whose elements share regulatory events, rather than adaptation, in common (5, 7) .
Little is known of the specific transduction pathways through which pressure overload can coordinately regulate an ensemble of "embryonic" or "fetal" genes. Mechanical stimulation including passive stretch (8) , or hormones induced by aortic constriction. (9) , may themselves induce hypertrophy or alter gene expression. There is increasing evidence that such signals might be coupled to cardiac mass through oncogeneencoded nuclear proteins such as c-fos and c-myc (5, 7, 10, 1 1), which have been implicated in the transduction of signals triggered by peptide growth factors (reviewed in references 12, 13). A potential role for peptide growth factors in cardiac hypertrophy, including transforming growth factor-# l (TGF#1; 14) and the heparin-binding acidic and basic fibroblast growth factors (aFGF, bFGF; 15), has been suggested by their presence in developing and adult cardiac myocytes or the extracellular matrix. Furthermore, growth factor production increases in myocytes surviving coronary artery ligation (16) , and autocrine or paracrine factors which accumulate in the myocardium during pressure-overload hypertrophy can stimulate cardiac growth in vitro (17) .
That cardiac myocytes might be targets for the action of peptide growth factors also is suggested by the responses of skeletal muscle cells. Both bFGF and aFGF are potent mitogens for skeletal myoblasts (18) and block the onset of the myogenic phenotype in undifferentiated cells, apparently differing only in potency (18, 19) . In contrast, TGF#31 suppresses the induction of muscle-specific proteins including MHC and a-actin (20) (21) (22) (23) in the absence of proliferative growth (21, 22) . These effects may occur at least in part by preventing the appearance or activity ofcertain muscle-specific DNA-binding proteins which modulate transcription (24) . Conversely, TGF (31 (21) and bFGF (25) also can down-regulate the muscle phenotype in myocytes which have not undergone terminal (irreversible) differentiation, whereas myocytes which are committed to fusion and the postmitotic state are reported to be refractory to the action of TGF,31 (20, 21) and bFGF (18) on muscle-specific genes.
However, it remains conjectural whether cellular events involved in growth factor signal transduction in fact play a role in cardiac hypertrophy triggered by pressure overload. First, the specific actions of serum growth factors are contingent both on cell type (26) and developmental state (27). Extensive disparities distinguish cardiac development from that of skeletal muscle and other existing model systems, ofwhich the most noteworthy, perhaps, are the ability to synthesize cardiac-specific proteins without exiting the cell cycle (28) , the uncoupling of DNA synthesis from mitotic division shortly after birth (29) , and, eventually, adaptive growth by cell enlargement (30) . At least one oncogene which extinguishes the ability of skeletal muscle to differentiate, SV40 large T antigen (31) , by contrast is permissive for a differentiated phenotype in cardiac myocytes (32) . Moreover, recent reports demonstrate that commitment of pluripotent cells to the skeletal muscle pathway during embryogenesis may be conferred by a hierarchy of myogenic "determination" genes (33) , most of which show homology to the nuclear oncogene c-myc, including MyoD 1 (34) and myogenin (35, 36) . In contrast, MyoDl and myogenin are not expressed in cardiac muscle (34, 36) , and the molecular mechanisms underlying cardiac ontogeny are not yet known. Together, these intrinsic differences suggest the likelihood that even genes which are co-expressed both by cardiac and skeletal myocytes must be subject to regulatory events which are lineage-specific. Genes such as a-cardiac actin (aCaA) and a-SkA, which are targets for the action of peptide growth factors, might thus be expected to possess responses to growth factor binding that differ fundamentally in the environment of cardiac vs. skeletal muscle cells. Finally, significant differences are known to exist among contractile protein gene families in their response to particular trophic signals. For example, unlike the MHC genes, a-CaA and a-SkA are relatively insensitive to fluctuations in thyroid hormone concentration (37 analyzed by Northern hybridization after 48 h in serum-free medium and 24 h in serum-free medium supplemented with the diluent used for growth factor studies. As shown in Fig. 1 A, the relative hybridization signal for aMHC vs. #MHC mRNA was about fivefold greater in cultured cardiac myocytes than in age-matched samples ofneonatal rat heart in vivo (4.10:0.8). To exclude the possibility that the preferential expression of aMHC was merely due to the concentration of thyroxine in the serum-free medium, steady-state levels of aactin mRNA also were analyzed. In overall agreement with the results for MHC gene expression, the relative intensity of aCaA vs. aSkA was about ninefold greater in the cultured cardiac myocytes than was found in the intact heart (6.47:0.670). Thus, the proportional expression of both aMHC and aCaA was augmented in the dissociated, cultured cells. As shown in Fig. 1 (aMHC, 0.14; fBMHC, 8.71). Whereas exogenous thyroid hormone prevents the transition between MHC isoforms after aortic constriction in vivo (3), all three peptide growth factors, at the concentration tested, produced down-regulation of aMHC and up-regulation of fMHC despite the presence of 1 nM thyroxine in the medium.
All three peptide growth factors also provoked changes in a-actin gene expression, which were distinct from the reciprocal regulation each produced in the MHC genes (Fig. 2) .
Whereas neither TGF#3I nor bFGF significantly altered aCaA transcript availability (TGF#31, 1.17; bFGF, 0.97), both growth factors stimulated approximately twofold expression of the aSkA gene, whose expression is associated with the embryonic or hypertrophic heart. Similar results were obtained in each of two independent experiments. Thus, in cardiac myocytes, four contractile protein genes exhibit a continuum of responses to TGF# I and bFGF, and the effects evoked were highly concordant. In contrast, aFGF differed in its consequences for expression of these sarcomeric actin genes, and was a potent inhibitor of both aCaA and aSkA in cultured cardiac myocytes.
A third sarcomeric actin, aSmA, is expressed in cardiac myocytes prior to the induction of either cardiac or skeletal actin (42) . This ontogenic relationship among the a-actin genes suggests two mutually exclusive hypotheses: that aFGF might suppress all three a-actin genes or, alternatively, that it might selectively stimulate aSmA, in the context of a phenotype even more primitive than that provoked by the other peptides. As shown in Fig. 2 , aSmA mRNA levels were increased by all three growth factors, and the greatest increase in aSmA expression was induced by aFGF (TGF#1, 1.69; bFGF, 1.75; aFGF, 2.45). Neither basal expression of aSmA nor its up-regulation by growth factors was detected in myocyte-depleted cultures enriched for cardiac mesenchymal cells (Fig. 3) . Similarly, these growth factors did not induce aSkA or aCaA ,> , A i; Fig. 2 ). For comparison, RNA isolated from cardiac myocytes treated with bFGF is shown at the right (Myo). Ethidium-bromide stained 28S ribosomal RNA is shown below.
in the fibroblastic cells (Parker, T. G., and M. D. Schneider, unpublished observations; cf. reference 26).
To examine the hypothesis that the differing effects of aFGF on contractile protein gene expression might be associated with distinct effects on myocardial growth in vitro, total RNA, protein content, and cell number were examined in myocardial cell cultures treated with each ofthe three peptides at the concentrations shown above (Fig. 4) . RNA and protein content were analyzed in four and five independent experiments, respectively, and cell number determined in seven. The interval examined was limited, to avoid the potentially confounding effect of sustained fibroblast proliferation and the contingency that longer exposure to a given factor might alter Myocyte-enriched 16 ,g per culture; P = 0.0029). During the interval tested, no effect ofbFGF on cell number was seen; differences in RNA content, similarly, were not statistically significant. These observations concur with evidence that bFGF increases cardiac myocyte number < 30% even after 7 d (43) and elicits mitotic growth in skeletal myocytes only in the presence of serum concentrations higher than those used here (18) . In contrast, at 24 h, aFGF had stimulated protein content more than twofold (5.47±0.22 ,g per culture; P = 0.0001), increased total RNA by 46% (110±5.6 vs. 161± 12.6 Mg per culture; P = 0.0098), and increased cell number -75% (2,290±180 vs. 3,980±318 cells/mm2; P = 0.0001). To exclude a preponderant effect of aFGF and bFGF on the residual nonmuscle cells, confluent myocyte-depleted cultures were examined for comparison (cf. references 10, 27; n = 2 for RNA and protein; n = 6 for cell number). RNA and protein content in the myocyte-depleted "fibroblast" cultures were comparable to those in parallel myocyte-enriched cultures, despite differences in cell number per square millimeter. After 48 h in the same serum-free medium used for cardiac myocytes and 24 h of growth factor stimulation, neither RNA, protein, nor cell number in mesenchymal cultures differed from the control values (Fig. 4) . Despite the potential for discordance between mesenchymal cells in the myocyte-depleted vs. myocyte-enriched cultures, these comparisons argue against the interpretation that the growth responses observed in cardiac "myocytes" occur chiefly or exclusively in the nonmuscle cells. Discussion Successful application of in vitro methods to the molecular biology of cardiac growth has been impeded by the absence of permanent cell lines, by evidence that conventional cell culture methods fail to maintain a fully differentiated phenotype, and by the paucity of physiologically relevant agonists. The investigations reported here demonstrate that cardiac myocytes are, directly or indirectly, targets for the action of three peptide growth factors: TGFB1, bFGF, and aFGF. Differentiated ventricular muscle cells possessed complex, selective responses to both TGFfl1 and bFGF: up-regulation of both "fetal" isoforms, aSkA and ,BMHC; down-regulation of aMHC expression; and little or no change in aCaA. Thus (44, 46) . Acidic FGF inhibits striated a-actin gene expression even at 1.25 ng/ml, 20-fold lower than the concentration of bFGF tested here (Parker, T. G., and M. D. Schneider, unpublished results). In contrast, aSmA mRNA levels were increased by all three growth factors. Studies utilizing the recombinant proteins would test the interpretation that the observed disparities between the action of acidic and basic FGF on cardiac myocytes are intrinsic to these peptides, and not the result of minor contaminants. The apparent association between proliferative growth and down-regulation of the striated a-actin genes merits additional investigation. By comparison, aFGF failed to provoke growth in myocyte-depleted cultures. While anomalous responses are unlikely in fibroblasts which have been passaged only once, the possibility exists that growth properties differ subtly between cardiac fibroblasts in primary vs. secondary culture, and it therefore will be useful to examine growth regulation in low-density cardiac cultures, where cell identity can be more readily ascertained (10).
The present data are consistent with the previous observation that serum exerts multifunctional effects on cardiac growth and actin gene expression which vary with the myocytes' precise stage of differentiation (27), and suggest the testable hypothesis that the ability of ventricular muscle cells to respond to aFGF declines during the transition from hyperplastic to hypertrophic growth. The relative expression of acidic and basic FGF by cardiac myocytes may itself be developmentally regulated (15) . As illustrated by disparities in the action of adrenergic agonists on ventricular muscle cells at different developmental stages (9, 48) (50) . Moreover, the possible complexities of autoregulation and cooperative interaction among these growth factors in the heart have not yet been explored. These unanswered questions may have particular interest in view of recent studies demonstrating both the existence of TGFs (14) and FGFs (15) in cardiac muscle cells during development, as well as the up-regulation of TGFs (16) and FGFs (51) after myocardial infarction or chronic ischemia. A role for cardiac growth factors during embryogenesis has been suggested in formation of the cardiac valves (52) and commitment of splanchnic mesoderm to the cardiac lineage (53) , akin to the synergistic action of FGF and TGFB analogues in skeletal muscle ontogeny (26, 47) . TGFB1 (54) and the FGFs (44) are the prototypes for two multigene families of peptides with complex and diverse effects on cell growth, differentiation, and morphogenesis: homologues including TGF,83 and -,B4 also may be expressed in cardiac muscle cells (55) .
The findings reported here suggest the provisional hypothesis that peptide growth factors which exist in cardiac myocytes and their extracellular matrix may contribute to cardiac hypertrophy and the associated "fetal" phenotype, through autocrine or paracrine mechanisms. Peptide growth factors might also be expected to affect nonmuscle components ofthe myocardium, through fibroblast proliferation or accumulation of the extracellular matrix, and add to the interstitial fibrosis which is often a hallmark of pathologic hypertrophy. The clinical relevance of TGFf3 for disease states and tissue repair has been recently reviewed (54) . The selective and heterogeneous actions shown by these peptide growth factors also might contribute to topographic or temporal discrepancies in the appearance of fetal myosin and'actin transcripts (56).
Finally, these results may provide evidence of previously unanticipated disparities between the program of differentiation in skeletal vs. cardiac muscle. In skeletal muscle, serum factors uniformly suppress all sarcomeric actin and MHC genes before irreversible differentiation (57, 58), and are not thought to modify muscle-specific gene expression once terminal differentiation has occurred (18, 20, 21, 57, 58) . In cardiac myocytes, on the other hand, TGF#l and bFGF selectively inhibited the "adult" aMHC transcript, concurrent with upregulation of all three fetal contractile protein genes examined thus far. This intricate set of events perhaps is most simply interpreted in the context ofa lineage-specific action of TGFfl 1 and bFGF on ventricular myocytes. Alternatively, the use of coding-sequence probes (57, 58) may have obscured possible transitions among the highly conserved actin and MHC isoforms, in myotubes exposed to mitogenic medium. Despite the fact that muscle cell receptors for both TGF(ll (59) and FGFs (60) down-regulate dramatically upon terminal differentiation, L6E9 myotubes remain able to up-regulate the fibronectin and collagen genes after treatment with TGFB1 (20) , as well as c-myc after exposure to serum (58) . The myogenic determination gene MyoDl is not constitutively expressed within the skeletal muscle lineage (cf. reference 34), but rather can be repressed by FGFs and TGFfl (61) or other inhibitors of muscle differentiation (62, 63) . Furthermore, the induction of myogenin itself accompanies growth factor withdrawal (36) .
Together, such observations are consistent with the inference that these nuclear proteins participate directly in the control of muscle-specific genes by growth factors. However, in cardiac muscle cells no protein with a corresponding structure and function has yet been identified. Cellular ras oncogenes produce a phenotype comparable to that provoked by TGF (31 (62-66) and suppress a-actin gene expression in skeletal muscle cells (62, 64) . It will be intriguing to determine whether activated ras alleles, by contrast, might selectively stimulate the transcription of aSmA, aSkA, or both when introduced into cardiac myocytes. Future attempts to interpret our results in the context of growth factor-inducible nuclear oncogenes and other ubiquitous transcription factors will need to account for the disparate effects of these peptide growth factors on myocardial gene expression.
